December 12, 2023 02:19 PM ESTUpdated December 15, 12:14 PM
R&D

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Ayisha Sharma

News Reporter

Dizal said its pe­riph­er­al T-cell lym­phoma drug can­di­date showed pos­i­tive ef­fi­ca­cy and safe­ty in a Phase II reg­is­tra­tional tri­al, paving the way for a US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times